PHILADELPHIA, July 28, 2015 /PRNewswire/ -- Clincierge™, the leading provider of specialized services and personalized support designed to overcome barriers to patient participation in clinical studies, today announced the expansion of its innovative "patient concierge" service into Cyprus. This event marks the 30th country where the company's high-touch, one-on-one services for patients and families are available to aid companies conducting clinical trials increase trial enrollment and improve patient retention, thus helping to ensure that costly studies complete on time and on budget.
"Since its inception two years ago, Clincierge has supported multiple studies internationally for pharmaceutical companies and contract research organizations with great success and overwhelming positive feedback from patients, research site personnel and sponsors," said Scott Gray, Clincierge chief executive officer. "By offering patients and their families personalized services in their own language from their own in-country coordinator, and providing patients ease-of-access to research sites, studies using Clincierge have seen increased enrollment and have maintained drop-out rates of less than 5%. Moreover, the cost of incorporating Clincierge services has averaged less than 1% to overall clinical trial costs."
Offering personalized support to trial participants and their families alleviates anxieties about trial-related travel, expenses and other issues that can get in the way of patients enrolling and staying in a clinical study. "The ultimate goal of Clincierge is to aid drug developers in reducing overall clinical testing time and cost by making clinical trials more patient-centric, thus helping ensure that new treatments get to the market and to patients who need them as swiftly as possible," Mr. Gray concluded.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.